U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H25NO
Molecular Weight 295.4186
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLEMANSERIN

SMILES

OC(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=AXNGJCOYCMDPQG-UHFFFAOYSA-N
InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2

HIDE SMILES / InChI
Molecular Formula C20H25NO
Molecular Weight 295.4186
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Glemanserin is a selective antagonist of the 5-HT2A receptor. It was tested in a clinical trial, in patients with generalized anxiety disorder, however, it did not demonstrate significant anxiolytic effects.

Originator

Merrell Dow Pharmaceuticals
12

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
5-hydroxytryptamine receptor 2A
69
Antagonist
2,778
 1.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Generalized anxiety disorder
32
 Primary
Phase I
428
Unknown

PubMed

Patents

JPH01279832A
1
JPH02138173A
1
JPH0418020A
1

Sample Use Guides

In Vivo Use Guide
In a clinical trial, glemanserin was given at a dose of 32 mg thrice daily.
Route of Administration: Oral
In Vitro Use Guide
Glemanserin (10(-7)-10(-6) M was incubated with guinea pig papillary muscle and dog Purkinje fiber. At that concentrations, the drug increased the action potential duration in both tissues with a maximum effective concentration of 10(-6) to 3 x 10(-6) M.
Substance Class Chemical
Record UNII
X96LS7MC5Z
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966